To evaluate the efficacy of guselkumab in improving skin clearance and symptoms in patients with moderate to severe plaque psoriasis who self-identify as non-White.
Key Findings:
74% of guselkumab-treated patients achieved IGA 0-1 compared to 0% in the placebo group.
57% of guselkumab patients achieved PASI 90 compared to 4% in the placebo group.
33% of guselkumab patients achieved complete clearance (IGA 0 and PASI 100) versus 0% in placebo.
Improvements in disease severity and body surface area were greater with guselkumab, maintained through week 48.
Adverse events occurred in 38% of guselkumab patients, primarily infections.
Interpretation:
Guselkumab demonstrated significant efficacy in improving psoriasis symptoms and quality of life in patients with darker skin tones, with sustained responses over time.
Limitations:
The trial was not powered for subgroup comparisons across different skin tones.
Crossover design limited long-term comparisons with placebo.
Sample size was modest.
Conclusion:
Guselkumab is a highly effective and durable treatment for psoriasis in individuals across all skin tones, with no new safety signals identified.
